Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.55 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.55 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.55 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.55 |
| ▸ | DUT | P33316 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | TK1 | P04183 | 2/20 | 0.45 |
| ▸ | TK2 | O00142 | 1/20 | 0.42 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21423137 | 1.00 | SLC28A1 (0.55) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL19657189 | 1.00 | SLC28A1 (0.55) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL1835932 | 1.00 | SLC28A1 (0.55) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL1835930 | 1.00 | SLC28A1 (0.55) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL1835935 | 1.00 | SLC28A1 (0.55) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL9083132 | 0.87 | LMNA (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3LMNA | |
| Deoxyuridine SCHEMBL24512520 | 0.85 | DUT (0.64) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| Deoxyuridine SCHEMBL19841232 | 0.85 | DUT (0.64) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| Deoxyuridine SCHEMBL391224 | 0.85 | DUT (0.64) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| Deoxyuridine SCHEMBL9708874 | 0.85 | DUT (0.64) | SLC28A1SLC28A2SLC29A1SLC28A3DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2880162-B1 | MODIFIED RNAI AGENTS | ALNYLAM PHARMACEUTICALS INC (US) | 2017-07-05 | — | — | EP | disclosed |
| US-8227594-B2 | Antiviral nucleosides | Kumar, Rakesh (CA) | 2012-07-24 | — | — | US | disclosed |
| US-8227594-B2 | Antiviral nucleosides | Kumar, Rakesh (CA) | 2012-07-24 | — | — | US | disclosed |
| US-20120184457-A1 | Modulation of miRNA Activity | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2012-07-19 | — | — | US | disclosed |
| US-20120184457-A1 | Modulation of miRNA Activity | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2012-07-19 | — | — | US | disclosed |
| EP-2322534-A1 | Antiviral nucleosides | Kumar, Rakesh (CA) | 2011-05-18 | — | — | EP | disclosed |
| US-20110104754-A1 | CELL CULTURE MEDIUM | GENETIX LIMITED | 2011-05-05 | — | — | US | disclosed |
| WO-2011015829-A1 | MODULATION OF MIRNA ACTIVITY | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-02-10 | — | — | WO | disclosed |
| EP-1818392-B1 | Cell culture medium | GENETIX LTD (GB) | 2010-08-25 | — | — | EP | disclosed |
| US-20100130440-A1 | ANTIVIRAL NUCLEOSIDES | KUMAR, RAKESH (CA) | 2010-05-27 | — | — | US | disclosed |
| US-20100130440-A1 | ANTIVIRAL NUCLEOSIDES | KUMAR, RAKESH (CA) | 2010-05-27 | — | — | US | disclosed |
| US-7589077-B2 | such as 5-iodo-O6-5'-cyclo-5,6-dihydro-3'-azido-3'-deoxythymidine for prophylaxis or diagnosis of viral diseases caused by hepatitis virus, herpes viruses such as Epstein-Barr virus | Kumar, Rakesh (CA) | 2009-09-15 | — | — | US | disclosed |
| US-7589077-B2 | such as 5-iodo-O6-5'-cyclo-5,6-dihydro-3'-azido-3'-deoxythymidine for prophylaxis or diagnosis of viral diseases caused by hepatitis virus, herpes viruses such as Epstein-Barr virus | Kumar, Rakesh (CA) | 2009-09-15 | — | — | US | disclosed |
| US-20070212778-A1 | Cell culture medium | GENETIX LIMITED | 2007-09-13 | — | — | US | disclosed |
| EP-1818392-A1 | Cell culture medium | Genetix Limited (GB) | 2007-08-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130440-A1 | ANTIVIRAL NUCLEOSIDES | PNP, ENTPD5, ADA | SLC28A1 27/4885SLC28A2 31/4885SLC29A1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.